Imai Yoichi

J-GLOBAL         Last updated: Nov 29, 2019 at 11:14
 
Avatar
Name
Imai Yoichi
Nickname
YIHematol
E-mail
imaiyo-tkyumin.ac.jp
Research funding number
10345209

Research Areas

 
 

Awards & Honors

 
Jan 2014
Development of novel targeted therapies in the treatment of multiple myeloma through elucidation of molecular mechanism of oncogenesis mediated by calcineurin, IMF-JAPAN Special Research Grant, IMF (International Myeloma Foundation)
 

Published Papers

 
HDAC inhibitors exert anti-myeloma effects through multiple modes of action.
Imai Y*, Hirano M, Kobayashi M, Futami M, and Tojo A. * corresponding author
Cancers   11(475) doi:10.3390/cancers11040475   Apr 2019   [Refereed]
Clinical efficacy of hematopoietic stem cell transplantation for adult adrenoleukodystrophy.
Matsukawa T, Yamamoto T, Honda A, Toya T, Ishiura H, Mitsui J, Tanaka M, Hao A, Shinohara A, Ogura M, Kataoka K, Seo S, Kumano K, Hosoi M, Narukawa, K, Yasunaga M, Maki, Ichikawa M, Nannya Y, Imai Y, Takahashi T, Takahashi Y, Nagasako Y, Yasaka K, Mano KK, Matsukawa MK, Miyagawa T, Hamada M, Sakuishi K, Hayashi T, Iwata A, Terao Y, Shimizu J, Goto J, Mori H, Kunimatsu, Shigeki Aoki S, Hayashi S, Nakamura F, Arai S, Momma K, Ogata K, Yoshida T, Abe O, Inazawa, J, Toda T, Kurokawa M, and Tsuji S.
Brain Communications      2019   [Refereed]
Safety of lenalidomide, dexamethasone, and cyclophosphamide in elderly Japanese patients with relapsed and refractory multiple myeloma: results of phase 1 study.
Tsukune Y, Sasaki M, Isoda A, Ando J, Koike M, Matsumoto M, Sawamura M, Tamura H, Handa H, Imai Y, Yahata Y and Komatsu N.
International Journal of Myeloma   9 1-6   2019   [Refereed]
Nested polymerase chain reaction with specific primers for Mucorales in the serum of patients with hematological malignancies.
Hirano M, Ota Y, Koibuchi T, Takei T, Takeda R, Kawamata T, Yokoyama K, Uchimaru K, Yotsuyanagi H, Imai Y*, Tojo A. * corresponding author
The Japanese Journal of Infectious Diseases      2019   [Refereed]
Nonmyelomatous ascites resulting from the increased secretion of vascular endothelial growth factor in multiple myeloma
Maki H, Nannya Y, Imai Y, Yamaguchi S, Kamikubo Y, Ichikawa M, Nakamura F, Kurokawa M.
Intern Med   57 725-727   2018   [Refereed]

Misc

 
Histone Deacetylase Inhibitos with or whitout AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dpendent Cytotoxicity As Well As Apoptosis
Mitsuhito Hirano, Yoichi Imai, Weng-Chit Ung, Kota Sato, Muneyoshi Futami, Arinobu Tojo.
Blood   132 4435   2018   [Refereed]

Books etc

 
Heat Shock Proteins in Signaling Pathways
Yoichi Imai and Arinobu Tojo (Part:Contributor, Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors.)
Springer   Jul 2019   

Conference Activities & Talks

 
HDAC and AKT inhibitors enhance anti-myeloma effects of daratumumab.
Mitsuhito Hirano, Yoichi Imai, Wengchif Ung, Kota Sato, Muneyoshi Futami, Arinobu Tojo.
2018   
HDAC and AKT inhibitors enhance anti-myeloma effects of dartumumab.
2018   
Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis.
Hirano M, Imai Y, Ung WC, Sato K, Futami M and Tojo A.
60th American Society of Hematology Annual Meeting   2018